What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NV01-A02 will be administered orally at a different dose once daily for 8 weeks. The formulation is a white, film-coated tablet, designed for use in patients with mild to moderate cognitive impairment.”In the company’s words, NCT06951854 on ClinicalTrials.gov
- Tested for
- Autism Spectrum Disorder (ASD
- Main trialPhase 2
- “This is a multicenter, randomized, double-blind, placebo-controlled, therapeutic exploratory Phase 2 clinical trial designed to evaluate the efficacy and safety of NV01-A02 in pediatric participants diagnosed with Autism Spectrum Disorder (ASD).”In the company’s words, NCT06951854 on ClinicalTrials.gov
Other drugs for Autism Spectrum Disorder (ASD
- CM-ATCuremark · Phase 3
- NTI164Fenix Innovation Group · Phase 3
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- TTYP01Shanghai Auzone Biological Technology Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 1 Sep 2025 | Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026